Milestone Pharmaceuticals Stock to Drop $0.06 in 3Q 2018
The stock of Milestone pharmaceutical company, which is part of the Arogya Group, is expected to drop $0,06 per share on Thursday.
The news follows news of the company’s acquisition of a controlling stake in Arocyst Pharmaceuticals in December 2018.
Arogyas Pharmaceuticals owns a stake in Milestone’s Arogynia division, which has a focus on treating diabetes.
It also owns a 20% stake in a subsidiary of Milestones Pharmaceuticals, which includes a medical device and biosimilars company.
The stock price of Miligenia Pharmaceuticals was also set to decline, although the company has posted a gain in the last 12 months.